JW2286: a single administration of JW2286 per dose
Placebo of JW2286: a single administration of Placebo of JW2286 per dose
Study summary
This clinical trial is a randomized, double-blind, placebo-controlled, single ascending dose, phase 1 clinical trial to evaluate the safety/tolerability and pharmacokinetic characteristics, and to explore food effect and ethnic difference of JW2286 after oral administration in healthy adults.
Eligibility
Sex
ALL
Min age
19 Years
Max age
50 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Healthy Korean or Caucasian volunteers
Exclusion Criteria:
* Individuals with a clinically significant disease or history
* Individuals with a history of a gastrointestinal disorder or surgery
* In the case of all female individuals with childbearing potential, except for those who are surgically sterile
Primary outcome measure(s)
Area under the plasma drug concentration-time curve from 0 to last (AUClast) of JW2286 — 0 to 168 hours Pharmacokinetic Characteristics Evaluation
Area under the plasma drug concentration-time curve from 0 to infinity (AUCinf) of JW2286 — 0 to 168 hours Pharmacokinetic Characteristics Evaluation
The maximum or peak concentration between zero and dosing interval (Cmax) of JW2286 — 0 to 168 hours Pharmacokinetic Characteristics Evaluation
Time of Maximum Concentration (Tmax) of JW2286 — 0 to 168 hours Pharmacokinetic Characteristics Evaluation
Trial sites (1)
Facility
City
Region
Status
Seoul National University Hospital Clinical Trial Center
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.